2-Chlorodeoxyadenosine therapy in advanced chronic lymphocytic leukaemia.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Nouvelle revue francaise d'hematologie

• Publication date

  1994-08-01

• Fields of study

  Medicine

• Identifiers
  PMID 7971251
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.

  1993cited by this paper
• 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.

  1993cited by this paper
• High complete remission rate from 2-chloro-2'-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count.

  1993cited by this paper
• Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.

  1992cited by this paper
• 2-Chlorodeoxyadenosine Treatment of Refractory Chronic Lymphocytic Leukemia.

  1991cited by this paper
• 2-Chlorodeoxyadenosine (2-CdA): A Potent Chemotherapeutic and Immunosuppressive Nucleoside.

  1991cited by this paper
• Fludarabine: a new agent with major activity against chronic lymphocytic leukemia.

  1989cited by this paper
• Recombinant alpha 2-interferon in the treatment of B chronic lymphocytic leukemia in early stages.

  1988cited by this paper
• 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia.

  1988cited by this paper
• Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute‐sponsored working group

  1988cited by this paper
• Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo.

  1980cited by this paper

• Chronic lymphocytic leukemia.

  2010cites this paper
• Treatment of relapsed chronic lymphocytic leukemia: old and new therapies.

  2006cites this paper
• Refractory Chronic Lymphocytic Leukemia

  2004cites this paper
• Chronic lymphocytic leukemia.

  2004cites this paper
• SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion for the approval of Litak. For information on changes after approval please refer to module 8. 1 Introduction LITAK contains the active substance cladribine (2-chloro-2’-deoxy- -D-adenosine or 2-chloro-6- amino-9-(2-deoxy-

  2004cites this paper
• A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211

  2003cites this paper
• Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study.

  1999cites this paper
• Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma.

  1998cites this paper
• Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Swiss Group for Clinical Cancer Research (SAKK).

  1998cites this paper
• Present status of purine analogs in the therapy of chronic lymphocytic leukemias.

  1997cites this paper
• Is there a place for 2-CDA in the treatment of B-CLL?

  1997cites this paper
• 2-Chlorodeoxyadenosine treatment in non-Hodgkin's Lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy: results of a multicentric experience

  1996cites this paper
• 2-chloro-2'-deoxyadenosine: clinical applications in hematology.

  1996cites this paper
• Why do drugs work in CLL?

  1996cites this paper
• Key issues in the treatment of chronic lymphocytic leukaemia (CLL)

  1995cites this paper
• 2-Chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL).

  1995cites this paper